These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6152368)

  • 1. Effects of (+)-cyanidanol-3 on chronic liver injury.
    Kovách G; Salamon F
    Acta Physiol Hung; 1984; 64(3-4):443-8. PubMed ID: 6152368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.
    Halmy L; Dávid K; Nagy I; Stotz G; Kelemen JT
    Acta Physiol Hung; 1984; 64(3-4):461-70. PubMed ID: 6152370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effect of (+)-cyanidanol-3 in toxic alcoholic liver disease and in chronic active hepatitis.
    Abonyi M; Kisfaludy S; Szalay F
    Acta Physiol Hung; 1984; 64(3-4):455-60. PubMed ID: 6397971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of chronic hepatitis. A comparative study of the effect azathioprine and (+)-cyanidanol-3].
    Aguilar Reina J; de la Santa López J; Cuadras Avellana CM; Kern A
    Fortschr Med; 1978 Jan; 96(2):75-9. PubMed ID: 74352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
    Pár A; Horváth T; Beró T; Kádas I; Pakodi F; Jávor T
    Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (+)-Cyanidanol-3 for alcoholic liver disease: results of a six-month clinical trial.
    World MJ; Aps EJ; Shaw GK; Thomson AD
    Alcohol Alcohol; 1984; 19(1):23-9. PubMed ID: 6149758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new therapy of hepatic insufficiency. Experiments with (+)-3--cyanidanol. Its importance in the treatment of alcoholic hepatitis].
    Traissac FJ; Borg R
    Minerva Dietol Gastroenterol; 1977; 23(3):237-42. PubMed ID: 372845
    [No Abstract]   [Full Text] [Related]  

  • 8. [A contribution as to the effect of (+)-Cyanidanol-3 in chronic liver disease (author's transl)].
    Sondern W; Leube G
    Med Klin; 1978 Oct; 73(41):1432-6. PubMed ID: 703670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of chronic diseases of the liver with catergen].
    Loginov AS; Dzhalalov KD; Blok IuE; Bendikov EA; Ausheva LKh
    Ter Arkh; 1986; 58(2):73-6. PubMed ID: 3704945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of therapy in chronic liver diseases. Double-blind study with cianidanol].
    Machalke K; Müller B
    Fortschr Med; 1982 Apr; 100(14):665-7. PubMed ID: 6123478
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of (+)-cyanidanol-3 (Catergen) in chronic active hepatitis. (Catergen plus prednisolone versus prednisolone in a controlled study).
    Pár A; Paál M; Kádas I; Kerekes E; Jávor T
    Acta Med Hung; 1983; 40(1):17-24. PubMed ID: 6664741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of alcohol-related liver disease with (+)-cyanidanol-3: a randomised double-blind trial.
    Colman JC; Morgan MY; Scheuer PJ; Sherlock S
    Gut; 1980 Nov; 21(11):965-9. PubMed ID: 6108901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of the effect of the administration of cathergen preparation in patients with chronic hepatic lesions].
    Maleev A; Tsvetkova V; Krŭstev Z; Kostova N; Lukanov L
    Vutr Boles; 1985; 24(5):39-43. PubMed ID: 4090451
    [No Abstract]   [Full Text] [Related]  

  • 14. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
    Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
    Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biological diagnosis of the type of liver disease in alcoholic patients with abnormal liver function tests].
    Naveau S; Montembault S; Balian A; Giraud V; Aubert A; Abella A; Capron F; Chaput JC
    Gastroenterol Clin Biol; 1999 Nov; 23(11):1215-24. PubMed ID: 10617832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors.
    St George A; Bauman A; Johnston A; Farrell G; Chey T; George J
    J Gastroenterol Hepatol; 2009 Mar; 24(3):399-407. PubMed ID: 19067776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver.
    Loguercio C; De Simone T; D'Auria MV; de Sio I; Federico A; Tuccillo C; Abbatecola AM; Del Vecchio Blanco C;
    Dig Liver Dis; 2004 Jun; 36(6):398-405. PubMed ID: 15248380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Catergen [(+)cyanidanol-3] on some haemostatic parameters in chronic liver diseases.
    Pfliegler G; Boda Z; Dalmi L; Weisz G; Misz M; Beck P
    Ther Hung; 1984; 32(1):19-25. PubMed ID: 6571189
    [No Abstract]   [Full Text] [Related]  

  • 19. Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease?
    Hickman IJ; Russell AJ; Prins JB; Macdonald GA
    Diabetes Res Clin Pract; 2008 Apr; 80(1):e10-2. PubMed ID: 18187226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of (+)-cyanidanol-3 on receptor activity of lymphocytes and hepatocytes and on hepatocyte-lymphocyte conjugation in alcoholic liver disease.
    Sipos J; Gabor V; Toth Z; Ribiczey P
    Int J Tissue React; 1984; 6(2):145-54. PubMed ID: 6203861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.